Pomanda estimates the enterprise value of ALMAC PHARMA SERVICES LIMITED at £286.5m based on a Turnover of £134m and 2.14x industry multiple (adjusted for size and gross margin).
almac pharma services limitedEstimated Valuation
£148.3m
Pomanda estimates the enterprise value of ALMAC PHARMA SERVICES LIMITED at £148.3m based on an EBITDA of £16.2m and a 9.17x industry multiple (adjusted for size and gross margin).
almac pharma services limitedEstimated Valuation
£135.5m
Pomanda estimates the enterprise value of ALMAC PHARMA SERVICES LIMITED at £135.5m based on Net Assets of £76.4m and 1.77x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Almac Pharma Services LimitedOverview
Almac Pharma Services Limited is a live company located in craigavon, BT63 5QD with a Companies House number of NI045055. It operates in the manufacture of pharmaceutical preparations sector, SIC Code 21200. Founded in January 2003, it's largest shareholder is
almac group (uk) ltd
with a 100% stake. Almac Pharma Services Limited is a mature,
mega sized company, Pomanda has estimated its turnover at
£134m with
healthy
growth in recent years.
Pomanda's financial health check has awarded Almac Pharma Services Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 4 areas for improvement. Company Health Check FAQs
Health Rating4out of 5
6 Strong
2 Regular
4 Weak
Size
annual sales of £134m, make it larger than the average company (£31m)
£134m - Almac Pharma Services Limited
£31m - Industry AVG
Growth
3 year (CAGR) sales growth of 7%, show it is growing at a faster rate (4.8%)
7% - Almac Pharma Services Limited
4.8% - Industry AVG
Production
with a gross margin of 26.3%, this company has a higher cost of product (33.4%)
26.3% - Almac Pharma Services Limited
33.4% - Industry AVG
Profitability
an operating margin of 6.4% make it as profitable than the average company (6.3%)
6.4% - Almac Pharma Services Limited
6.3% - Industry AVG
Employees
with 1227 employees, this is above the industry average (98)
1227 - Almac Pharma Services Limited
98 - Industry AVG
Pay Structure
on an average salary of £43.6k, the company has a lower pay structure (£65k)
£43.6k - Almac Pharma Services Limited
£65k - Industry AVG
Efficiency
resulting in sales per employee of £109.2k, this is less efficient (£299.2k)
£109.2k - Almac Pharma Services Limited
£299.2k - Industry AVG
Debtor Days
it gets paid by customers after 61 days, this is near the average (56 days)
61 days - Almac Pharma Services Limited
56 days - Industry AVG
Creditor Days
its suppliers are paid after 46 days, this is slower than average (35 days)
46 days - Almac Pharma Services Limited
35 days - Industry AVG
Stock Days
it holds stock equivalent to 49 days, this is less than average (106 days)
49 days - Almac Pharma Services Limited
106 days - Industry AVG
Cash Balance
has cash to cover current liabilities
for 0 weeks, this is less cash available to meet short term requirements (10 weeks)
0 weeks - Almac Pharma Services Limited
10 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 55.6%, this is a higher level of debt than the average (45.1%)
55.6% - Almac Pharma Services Limited
45.1% - Industry AVG
ALMAC PHARMA SERVICES LIMITED financials
EXPORT
Almac Pharma Services Limited's latest turnover from September 2023 is £134 million and the company has net assets of £76.4 million. According to their latest financial statements, Almac Pharma Services Limited has 1,227 employees and maintains cash reserves of £440 as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Sep 2019
Sep 2018
Sep 2017
Sep 2016
Sep 2015
Sep 2014
Sep 2013
Sep 2012
Sep 2011
Sep 2010
Sep 2009
Turnover
133,999,805
126,318,676
114,910,607
108,250,644
91,315,765
76,836,094
69,660,684
64,406,365
57,746,436
55,264,606
42,428,462
37,540,985
30,828,021
28,476,311
24,504,766
Other Income Or Grants
Cost Of Sales
98,753,484
89,031,478
75,667,961
74,929,614
62,672,981
55,242,190
48,280,529
42,854,285
41,336,594
41,156,347
29,912,980
26,535,857
23,080,581
22,736,004
17,077,674
Gross Profit
35,246,321
37,287,198
39,242,646
33,321,030
28,642,784
21,593,904
21,380,155
21,552,080
16,409,842
14,108,259
12,515,482
11,005,128
7,747,440
5,740,307
7,427,092
Admin Expenses
26,682,265
24,200,276
23,782,592
21,339,033
20,659,883
17,994,393
16,082,462
12,714,975
11,064,721
9,960,710
10,439,292
9,456,738
7,747,185
7,197,259
8,239,362
Operating Profit
8,564,056
13,086,922
15,460,054
11,981,997
7,982,901
3,599,511
5,297,693
8,837,105
5,345,121
4,147,549
2,076,190
1,548,390
255
-1,456,952
-812,270
Interest Payable
1,483,339
527,189
464,248
762,420
439,089
389,762
239,978
191,879
357,225
492,162
394,611
310,382
322,480
226,006
75,587
Interest Receivable
1,207
189,275
120,257
46,664
22,481
23,179
8,316
6,805
6,220
9,689
2,547
5,482
36
331
251
Pre-Tax Profit
7,081,924
12,749,008
15,116,063
11,266,241
7,566,293
3,232,928
5,066,031
8,652,031
4,994,116
3,665,076
1,684,126
1,243,490
-322,189
-1,682,627
-887,606
Tax
-2,189,033
-2,529,444
-4,278,694
-2,551,634
-1,445,120
-538,402
-859,010
-1,270,415
-1,012,679
-745,511
190,751
-34,267
174,888
826,980
-56,816
Profit After Tax
4,892,891
10,219,564
10,837,369
8,714,607
6,121,173
2,694,526
4,207,021
7,381,616
3,981,437
2,919,565
1,874,877
1,209,223
-147,301
-855,647
-944,422
Dividends Paid
Retained Profit
4,892,891
10,219,564
10,837,369
8,714,607
6,121,173
2,694,526
4,207,021
7,381,616
3,981,437
2,919,565
1,874,877
1,209,223
-147,301
-855,647
-944,422
Employee Costs
53,508,358
47,852,830
40,983,892
37,055,694
29,662,345
25,886,343
22,478,600
18,841,743
16,783,471
15,057,577
13,612,031
11,245,225
9,638,876
9,007,180
7,655,485
Number Of Employees
1,227
1,190
1,012
892
784
719
639
565
510
470
436
371
337
317
284
EBITDA*
16,162,921
20,354,952
22,020,245
17,453,262
12,048,049
7,240,438
7,966,426
11,564,143
7,874,810
6,414,846
4,081,407
3,231,102
1,577,549
243,844
2,102,465
* Earnings Before Interest, Tax, Depreciation and Amortisation
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Sep 2019
Sep 2018
Sep 2017
Sep 2016
Sep 2015
Sep 2014
Sep 2013
Sep 2012
Sep 2011
Sep 2010
Sep 2009
Tangible Assets
108,252,920
75,857,238
63,481,895
59,143,766
42,992,352
42,275,767
40,950,053
33,797,324
30,551,227
30,827,321
28,960,323
24,396,881
21,304,894
19,716,638
18,124,478
Intangible Assets
13,081,441
1,270,337
1,396,938
1,236,154
928,082
518,369
275,814
319,170
259,620
343,705
441,815
168,067
304,585
478,191
634,344
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
121,334,361
77,127,575
64,878,833
60,379,920
43,920,434
42,794,136
41,225,867
34,116,494
30,810,847
31,171,026
29,402,138
24,564,948
21,609,479
20,194,829
18,758,822
Stock & work in progress
13,257,687
10,843,029
11,890,198
11,440,467
12,308,137
11,355,659
11,345,598
9,665,305
9,467,673
9,032,063
9,313,942
5,787,223
4,925,388
3,893,083
3,797,168
Trade Debtors
22,603,974
24,252,935
12,679,286
12,708,752
12,426,375
8,220,808
5,930,367
5,547,505
4,126,454
3,460,822
3,639,013
2,951,148
1,928,416
1,661,894
1,938,339
Group Debtors
3,688,795
3,710,763
9,420,239
5,196,112
6,305,284
6,363,892
6,349,821
6,041,331
4,791,224
8,484,221
7,007,540
2,473,238
3,911,178
5,362,118
1,780,108
Misc Debtors
11,151,947
7,549,962
5,829,766
4,360,397
5,613,683
7,187,506
5,719,451
4,943,460
943,748
1,201,799
1,824,833
1,141,252
1,119,740
1,569,427
1,568,581
Cash
440
1,572
1,220
1,213
1,282
46,655
7,902
111,518
529
21,861
88,536
10,165
13,765
163,626
3,392
misc current assets
567,203
500,239
98,149
85,426
total current assets
50,702,843
46,358,261
39,820,709
34,207,180
37,155,000
33,741,723
29,853,378
26,407,268
19,415,054
22,200,766
21,873,864
12,363,026
11,898,487
12,650,148
9,087,588
total assets
172,037,204
123,485,836
104,699,542
94,587,100
81,075,434
76,535,859
71,079,245
60,523,762
50,225,901
53,371,792
51,276,002
36,927,974
33,507,966
32,844,977
27,846,410
Bank overdraft
75,596
1,701,791
848,635
1,193,457
952,300
596,598
824,238
1,156,234
211,602
502,535
556,972
64,923
Bank loan
Trade Creditors
12,503,740
6,420,374
4,924,245
3,548,442
3,202,731
3,152,861
3,727,967
4,579,569
3,107,096
3,751,514
3,545,263
3,703,112
1,695,520
2,171,989
2,276,097
Group/Directors Accounts
38,723,349
97,300
3,293,446
12,921,678
15,080,407
13,824,221
9,044,830
9,780,905
16,560,060
19,869,181
9,810,256
other short term finances
226,505
267,427
262,730
hp & lease commitments
1,411,909
1,396,494
1,228,633
1,445,109
40,698
35,228
27,839
28,120
11,698
9,802
15,468
7,271
other current liabilities
9,546,384
12,651,968
9,518,202
10,556,315
7,754,861
8,012,321
5,534,480
3,887,682
2,865,326
3,230,683
2,132,470
2,318,932
11,537,085
10,584,238
6,306,469
total current liabilities
62,185,382
20,566,136
15,671,080
18,918,908
25,621,759
27,355,957
24,575,391
18,755,231
16,361,623
24,376,297
26,718,616
16,051,173
13,735,140
13,313,199
8,647,489
loans
27,402,696
24,406,988
26,517,964
1,032,050
915,190
317,403
640,508
53,230
62,802
82,406
12,536
hp & lease commitments
12,471,981
13,701,348
12,203,494
13,258,982
61,041
82,464
45,449
73,288
26,615
31,401
41,203
6,268
Accruals and Deferred Income
12,807,323
9,770,822
9,330,241
7,531,092
5,695,192
5,809,179
7,046,522
7,030,014
7,153,956
369,840
422,386
554,120
679,817
606,275
other liabilities
359,985
provisions
8,123,665
15,783,136
12,316,658
8,758,178
8,296,130
8,039,522
6,723,336
5,109,216
4,897,268
4,647,518
4,106,070
2,766,266
2,188,766
914,642
331,422
total long term liabilities
33,402,969
31,363,738
27,692,064
25,169,163
10,814,266
10,661,666
10,680,144
10,151,842
9,629,205
2,725,000
2,454,223
1,811,787
1,648,503
1,137,138
771,986
total liabilities
95,588,351
51,929,874
43,363,144
44,088,071
36,436,025
38,017,623
35,255,535
28,907,073
25,990,828
27,101,297
29,172,839
17,862,960
15,383,643
14,450,337
9,419,475
net assets
76,448,853
71,555,962
61,336,398
50,499,029
44,639,409
38,518,236
35,823,710
31,616,689
24,235,073
26,270,495
22,103,163
19,065,014
18,124,323
18,394,640
18,426,935
total shareholders funds
76,448,853
71,555,962
61,336,398
50,499,029
44,639,409
38,518,236
35,823,710
31,616,689
24,235,073
26,270,495
22,103,163
19,065,014
18,124,323
18,394,640
18,426,935
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Sep 2019
Sep 2018
Sep 2017
Sep 2016
Sep 2015
Sep 2014
Sep 2013
Sep 2012
Sep 2011
Sep 2010
Sep 2009
Operating Activities
Operating Profit
8,564,056
13,086,922
15,460,054
11,981,997
7,982,901
3,599,511
5,297,693
8,837,105
5,345,121
4,147,549
2,076,190
1,548,390
255
-1,456,952
-812,270
Depreciation
5,738,703
6,864,358
6,192,300
5,306,448
3,900,331
3,533,121
2,560,927
2,623,971
2,433,626
2,166,126
1,871,148
1,498,308
1,397,628
1,522,357
2,836,865
Amortisation
1,860,162
403,672
367,891
164,817
164,817
107,806
107,806
103,067
96,063
101,171
134,069
184,404
179,666
178,439
77,870
Tax
-2,189,033
-2,529,444
-4,278,694
-2,551,634
-1,445,120
-538,402
-859,010
-1,270,415
-1,012,679
-745,511
190,751
-34,267
174,888
826,980
-56,816
Stock
2,414,658
-1,047,169
449,731
-867,670
952,478
10,061
1,680,293
197,632
435,610
-281,879
3,526,719
861,835
1,032,305
95,915
3,797,168
Debtors
1,931,056
7,584,369
5,664,030
-2,080,081
2,573,136
3,772,567
1,467,343
6,670,870
-3,285,416
675,456
5,905,748
-393,696
-1,634,105
3,306,411
5,287,028
Creditors
6,083,366
1,496,129
1,375,803
345,711
49,870
-575,106
-851,602
1,472,473
-644,418
206,251
-157,849
2,007,592
-476,469
-104,108
2,276,097
Accruals and Deferred Income
-69,083
3,574,347
761,036
4,637,354
-371,447
1,240,498
1,663,306
898,414
6,418,759
1,468,053
-608,848
-9,349,887
827,150
4,351,311
6,912,744
Deferred Taxes & Provisions
-7,659,471
3,466,478
3,558,480
462,048
256,608
1,316,186
1,614,120
211,948
249,750
541,448
1,339,804
577,500
1,274,124
583,220
331,422
Cash flow from operations
7,982,986
19,825,262
17,323,109
23,294,492
7,012,346
4,900,986
6,385,604
6,008,061
15,736,028
7,491,510
-4,587,202
-4,036,099
3,979,042
2,498,921
2,481,716
Investing Activities
capital expenditure
-51,805,651
-19,516,772
-11,059,104
-21,930,751
-5,191,446
-5,209,196
-9,778,106
-6,032,685
-2,169,510
-4,036,185
-6,842,407
-4,638,181
-2,991,944
-3,136,803
-21,673,557
Change in Investments
cash flow from investments
-51,805,651
-19,516,772
-11,059,104
-21,930,751
-5,191,446
-5,209,196
-9,778,106
-6,032,685
-2,169,510
-4,036,185
-6,842,407
-4,638,181
-2,991,944
-3,136,803
-21,673,557
Financing Activities
Bank loans
Group/Directors Accounts
38,626,049
97,300
-3,293,446
-9,628,232
-2,158,729
1,256,186
4,779,391
-736,075
-6,779,155
-3,309,121
10,058,925
9,810,256
Other Short Term Loans
-226,505
-40,922
4,697
262,730
Long term loans
-27,402,696
2,995,708
-2,110,976
25,485,914
116,860
597,787
-323,105
587,278
-9,572
-19,604
69,870
12,536
Hire Purchase and Lease Commitments
-1,213,952
1,665,715
-1,271,964
14,602,352
-15,953
44,404
-28,120
63,095
-2,890
-15,468
43,132
13,539
other long term liabilities
-359,985
359,985
share issue
-2,854,987
-6,016,859
1,247,767
1,163,272
-268,532
-123,016
823,352
19,371,357
interest
-1,482,132
-337,914
-343,991
-715,756
-416,608
-366,583
-231,662
-185,074
-351,005
-482,473
-392,064
-304,900
-322,444
-225,675
-75,336
cash flow from financing
8,527,269
4,420,809
-7,020,377
26,889,291
-2,700,935
1,490,872
4,201,201
-8,046
-13,159,481
-2,938,884
11,303,120
9,262,899
-445,460
597,677
19,296,021
cash and cash equivalents
cash
-1,132
352
7
-69
-45,373
38,753
-103,616
110,989
-21,332
-66,675
78,371
-3,600
-149,861
160,234
3,392
overdraft
-75,596
-1,626,195
853,156
-344,822
241,157
355,702
-227,640
-331,996
944,632
-290,933
-54,437
492,049
64,923
change in cash
-1,132
352
75,603
1,626,126
-898,529
383,575
-344,773
-244,713
206,308
265,321
-866,261
287,333
-95,424
-331,815
-61,531
almac pharma services limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for almac pharma services limited. Get real-time insights into almac pharma services limited's credit score, group structure and payment trends.
Perform a competitor analysis for almac pharma services limited by selecting its closest rivals, whether from the MANUFACTURING sector, other mega companies, companies in BT63 area or any other competitors across 12 key performance metrics.
almac pharma services limited Ownership
ALMAC PHARMA SERVICES LIMITED group structure
Almac Pharma Services Limited has no subsidiary companies.
The sole shareholder of Almac Pharma Services Limited is Almac Group (Uk) Ltd.
almac group (uk) ltd
100%
almac pharma services limited directors
Almac Pharma Services Limited currently has 6 directors.
The longest serving directors include
Mr Alan Armstrong (Feb 2003) and
Mr Graeme McBurney (Dec 2003).
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 11 charges/mortgages relating to almac pharma services limited. Currently there are 7 open charges and 4 have been satisfied in the past.
almac pharma services limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ALMAC PHARMA SERVICES LIMITED. This can take several minutes, an email will notify you when this has completed.
almac pharma services limitedCompanies House Filings - See Documents
